SCHEMBL6318890

SCHEMBL6318890

Cc1ccsc1-c1noc(N)c1C(=O)NCc1cccc(Cl)c1

nearest known ligand 0.56

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 2/20 0.44
NPC1 O15118 2/20 0.43
RAB9A P51151 1/20 0.43
POLB P06746 2/20 0.43
HPGD P15428 1/20 0.42
MEN1 O00255 1/20 0.42
HCRTR1 O43613 1/20 0.42
KMT2A Q03164 1/20 0.42
MAPT P10636 1/20 0.42
PTGER4 P35408 1/20 0.41
GAA P10253 1/20 0.41
ALDH1A1 P00352 2/20 0.41
ADORA3 P0DMS8 1/20 0.41
ADORA2A P29274 1/20 0.41
ADORA2B P29275 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6317256 0.91 NPC1 (0.49) NPC1RAB9AHPGDMEN1KMT2A
SCHEMBL6316125 0.90 POLB (0.47) ADORA1POLBHPGDMEN1KMT2A
SCHEMBL6323637 0.89 LMNA (0.48) ADORA1RAB9APOLBHPGDKMT2A
SCHEMBL6318418 0.88 POLB (0.53) NPC1RAB9APOLBMEN1KMT2A
SCHEMBL6322463 0.86 NPC1 (0.46) ADORA1NPC1RAB9APOLBHPGD
SCHEMBL6318410 0.85 POLB (0.42) POLBKMT2AGAAALDH1A1
SCHEMBL6315404 0.84 KMT2A (0.47) POLBHPGDMEN1KMT2AMAPT
SCHEMBL6315224 0.82 ADORA1 (0.48) ADORA1NPC1HPGDMEN1HCRTR1
SCHEMBL6316275 0.82 KMT2A (0.56) NPC1POLBHPGDKMT2AMAPT
SCHEMBL6324517 0.82 NAMPT (0.47) POLBMEN1KMT2AGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 ADORA1 1592/4885NPC1 3741/4885RAB9A 1754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.